Nyrada Inc – Brain Injury Program Preclinical Development Update

New brain injury drug candidate NYR-BI03 to be advanced instead of NYR-BI02 due to
demonstrated superior potency and safety profile, overcoming limitations identified with
NYR-BI02 during GLP preclinical studies
• NYR-BI03 to be evaluated in WRAIR TBI efficacy study and stroke model study in 2H CY2023, in
parallel to the required preclinical studies
• Remaining preclinical safety and toxicology studies paused until 2H CY2023, while the
manufacture of sufficient quantities of NYR-BI03 is completed
• Funding in place to pursue preclinical development of NYR-BI03 in preparation for a Phase I
first-in-human study
• Nyrada to present abstract on brain injury drug target at the US Military Health System
Research Symposium in August